Revenue and Losses - Revenue for the three months ended March 31, 2025, was $979,977, compared to $0 for the same period in 2024, indicating a significant increase[12] - Net loss for the three months ended March 31, 2025, was $(11,495,947), compared to $(9,995,136) for the same period in 2024, representing an increase in losses[12] - For the nine months ended March 31, 2025, the company reported a net loss of $36.6 million, compared to a net loss of $29.1 million for the same period in 2024, indicating a 26% increase in losses year-over-year[21] - The company reported a net loss per share of $(0.14) for the three months ended March 31, 2025, compared to $(0.19) for the same period in 2024[12] Expenses and Financial Performance - Gross loss for the three months ended March 31, 2025, was $(2,689,960), while the gross loss for the nine months ended March 31, 2025, was $(8,003,944)[12] - Total operating expenses for the nine months ended March 31, 2025, were $26,245,059, compared to $25,433,780 for the same period in 2024, reflecting a slight increase[12] - The company incurred stock-based compensation expenses of $12.8 million for the nine months ended March 31, 2025, compared to $12.3 million in the same period of 2024[21] - Stock-based compensation expense for the period reached $6,330,914, contributing to the overall financial performance[15] Assets and Liabilities - Cash and cash equivalents as of March 31, 2025, were $2,849,257, down from $7,001,786 as of June 30, 2024[9] - Total current assets increased to $23,285,228 as of March 31, 2025, compared to $18,406,048 as of June 30, 2024[9] - Total liabilities decreased to $10,851,323 as of March 31, 2025, from $16,207,492 as of June 30, 2024[9] - Stockholders' equity increased to $65,605,927 as of March 31, 2025, compared to $61,467,640 as of June 30, 2024[9] Inventory and Production - As of March 31, 2025, the total inventory was $252,945,000, an increase from $154,320,000 as of June 30, 2024, representing a growth of 63.9%[49] - The cost of goods sold for the three months ended March 31, 2025, was $3.7 million, significantly exceeding the related revenue, attributed to the depreciation of fixed assets and production process finalization[36] - The Company expects the high cost of goods sold to continue rising but to decrease as a percentage of revenue as production scales and efficiencies are gained[36] Financing and Capital Structure - The company issued 8,773,586 common shares and warrants pursuant to registered direct offerings, raising $13,911,000[16] - The company completed an At-The-Market offering, resulting in the issuance of 5,938,786 shares, raising $6,327,168[15] - The Company’s shareholders approved an increase in authorized shares from 80 million to 250 million, allowing for the reclassification of derivative liabilities totaling $2.1 million to additional paid-in capital[62] - The Company has authorized a total of 250,000,000 shares of common stock as of March 31, 2025, following an amendment to increase the number of authorized shares[93] Grants and Tax Credits - The Company was awarded a tax credit of up to $40.5 million through the 48C program for a new battery recycling facility in the U.S.[56] - The Company received a grant award of $144 million from the U.S. DOE for the construction of a lithium-ion battery recycling facility, with cumulative funds invoiced totaling $0.2 million as of March 31, 2025, representing 0.2% of total eligible reimbursements[57] - The Company recognized $4.3 million of invoiced government funds as an offset to research and development costs during the nine months ended March 31, 2025[50] Operational Challenges and Future Outlook - The company has a significant reliance on obtaining debt or equity financing to continue operations, with substantial doubt regarding its ability to continue as a going concern for the next 12 months[25] - The company is focused on increasing domestic production of critical battery materials and developing new technologies for extraction and recycling of lithium-ion batteries[22] - The continuation of the company as a going concern is dependent on generating profit from operations and obtaining financing, with substantial doubt existing regarding its ability to continue for the next 12 months[25] Shareholder and Stock Activity - The weighted average shares outstanding increased to 85,090,957 for the three months ended March 31, 2025, from 51,993,863 for the same period in 2024[12] - The total unvested share awards as of March 31, 2025, were 7,816,136, with a weighted average grant date fair value of $2.18 per unit[110] - The Company issued 14,360,308 total warrants during the nine months ended March 31, 2025, including 3,548,426 warrants from a private placement[106] Depreciation and Impairment - The Company recognized a depreciation expense of $3.8 million for the nine months ended March 31, 2025, significantly higher than $121,075 in the previous year[21] - The Company recognized a depreciation expense of $1.2 million for the three months ended March 31, 2025, compared to $39,665 for the same period in 2024[65] - An impairment charge of $10.3 million was recorded on assets held-for-sale for the fiscal year ended June 30, 2024[67]

FORM 10‑Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission file number: 000-53316 SOBR SAFE, INC. (Exact name of registrant as specified in its charter) 10-Q 1 sobr_10q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Re ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-42152 Eureka Acquisition Corp (Exact name of registrant as specified in its charter) Cayman Islands N/A (State or other jurisdiction of (I.R. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-42152 Eureka Acquisition Corp (Exact name of registrant as specified in its charter) Cayman Islands N/A (State or other jurisdiction of (I.R. ...

Revenue Performance - Q1'25 revenue decreased to $1.6M from $2.2M in Q1'24, a decline of approximately 26% year-over-year[10] - License fee revenue fell to $1.1M in Q1'25 from $1.95M in Q1'24, reflecting a significant impact from a $1.2M contract in Q1'24[10] - Service revenues increased by 28% to $272.6K in Q1'25 from $213.1K in Q1'24, driven by a 37% rise in recurring maintenance and support revenue[11] - Hardware sales surged to $235.8K in Q1'25 from $17.6K in Q1'24, attributed to increased purchases of fingerprint biometric scanners[12] Financial Metrics - Gross margin for Q1'25 was 82.6%, down from 86.3% in Q1'24, due to lower revenue and higher lower-margin hardware sales[13] - Operating expenses decreased by 17.7% to $1.97M in Q1'25 from $2.39M in Q1'24, with SG&A expenses down 23%[14] - Net loss for the three months ended March 31, 2025, was $736,545, compared to a net loss of $510,285 for the same period in 2024, reflecting a 44.3% increase in losses[25] - Total current liabilities decreased to $3,465,616 from $4,553,536, a reduction of 24%[23] - Total stockholders' equity increased to $7,527,053 from $3,772,031, showing a growth of 99%[23] - Deferred revenue increased to $928,291 from $773,267, indicating a growth of 20.1%[23] - Net cash used in operating activities was $835,312, compared to a net cash provided of $297,084 in the prior year, indicating a shift in cash flow dynamics[25] Cash Position - Cash position improved to $3.1M as of March 31, 2025, compared to $438K at the end of 2024[16] - Cash and cash equivalents rose significantly to $3,133,752, up from $437,604, marking a 615.5% increase[25] - The company reported a net increase in cash and cash equivalents of $2,696,148 for the period, compared to an increase of $179,049 in the previous year[25] - Proceeds from the exercise of warrants amounted to $3,813,057, a significant increase compared to $1,400 in the previous year[25] Growth Expectations - The company expects significant revenue growth from a long-term financial services customer starting in 2026 due to expanded deployments[2] - BIO-key is focusing on expanding its presence in the EMEA region, anticipating improved revenue and margins in 2025[8] - The company serves over 100 institutions with more than 4M end users in the state, local, and educational markets[6] Asset Management - Total assets increased to $11,183,676 from $8,615,560, representing a growth of 29.5% year-over-year[23] - Inventory levels decreased slightly to $357,842 from $378,307, a decline of 5.4%[23]

Financial Performance - Net loss for Q1 2025 was approximately $3,705,000, a decrease of 36% from a net loss of $5,817,000 in Q1 2024[217]. - Revenues from the Ampligen® Cost Recovery Program decreased to $16,000 in Q1 2025 from $40,000 in Q1 2024, a decline of $24,000[218]. - Research and Development costs decreased to approximately $1,080,000 in Q1 2025 from $1,951,000 in Q1 2024, reflecting a reduction of approximately $871,000[222]. - General and Administrative expenses decreased to approximately $2,545,000 in Q1 2025 from $3,815,000 in Q1 2024, a decrease of approximately $1,270,000[224]. - Cash used in operating activities decreased to approximately $2,361,000 in Q1 2025 from $4,815,000 in Q1 2024, a reduction of $2,454,000[226]. Cash and Equity Position - As of March 31, 2025, the company had approximately $2,247,000 in cash and cash equivalents, a decrease of approximately $1,730,000 from December 31, 2024[229]. - Stockholders' equity was below the minimum requirements for continued listing on the NYSE American, with a deficit of approximately $3.9 million as of March 31, 2025[237]. Securities and Offerings - The company filed a Universal Shelf Registration Statement to register the offering of up to $100,000,000 of various securities, which has not yet been declared effective[242]. - An Equity Distribution Agreement was entered into with Maxim Group LLC to issue and sell up to $3,000,000 of common stock under the Registration Statement[243]. - The company has entered into a Purchase Agreement with Atlas Sciences, LLC, committing to purchase up to $15 million of common stock over a 24-month period[254]. - As of March 31, 2025, a total of 3,082,961 shares have been issued under the Purchase Agreement for approximately $398,000 after clearing costs[264]. - The company issued 5,640,958 shares of common stock and Class A and B common warrants to a single accredited investor, with an exercise price of $0.363 per share[265]. - The company received aggregate gross proceeds of approximately $1.26 million from the issuance of 4,653,036 shares and associated warrants in a registered direct offering[272]. - The company has agreed to pay Maxim a commission of 3.0% on the aggregate gross proceeds from each sale of common stock under the Sales Agreement[246]. - The total estimated expenses for the offering, excluding compensation to Maxim, will be approximately $54,000[246]. - The company cannot sell shares below the Minimum Price that would represent more than 19.99% of the outstanding shares without stockholder approval[258]. - The initial commitment fee to Atlas was paid through the issuance of 338,600 shares of common stock, equal to 1.0% of the Commitment Amount[260]. - The Common Warrants issued in the Transactions are classified as equity within the consolidated financial statements, with proceeds allocated totaling approximately $2.5 million[270]. - The registration statement for the resale of shares issued under the Purchase Agreement was declared effective on May 1, 2024[255].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ______________ Commission File Number: 001-37537 Houlihan Lokey, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorp ...

Financial Performance - Net revenues for the three months ended March 31, 2025, were approximately $2.14 million, a decrease of approximately $0.2 million or 8.5% from $2.34 million for the same period in 2024[168]. - The net loss from continuing operations for Q1 2025 was $5.36 million, compared to a net loss of $7.76 million in Q1 2024[168]. - Adjusted EBITDA from continuing operations for the three months ended March 31, 2025 was approximately $(3.96) million, an improvement from $(6.44) million in the same period of 2024[188]. - For the three months ended March 31, 2025, the company's net revenues from continuing operations were $2,143,058, a decrease of 8.5% compared to $2,342,918 for the same period in 2024[236]. Vehicle Sales and Revenue Breakdown - Vehicle sales accounted for $1.81 million or 84.5% of total net revenues in Q1 2025, compared to $1.52 million or 65.0% in Q1 2024[170]. - Vehicle sales for the three months ended March 31, 2025, were $1,837,054, down 27% from $2,514,777 in 2024[236]. - Spare-parts sales decreased significantly to $242,276 in 2025 from $828,785 in 2024, representing a decline of approximately 70.8%[236]. - The company's revenue from Asia increased to $1,174,031 in 2025, up 6.3% from $1,104,475 in 2024, while revenue from Europe and America decreased significantly[237]. Operating Expenses - Total operating expenses for Q1 2025 were $6.50 million, down from $8.04 million in Q1 2024, reflecting a reduction in research and development expenses[168]. - Selling and marketing expenses increased by approximately $0.2 million or 25.7% to approximately $0.8 million for the three months ended March 31, 2025, primarily due to increased freight costs[178]. - General and administrative expenses decreased by approximately $1.0 million or 16.6% to approximately $4.9 million for the three months ended March 31, 2025, attributed to reductions in various operational costs[179]. - Research and development expenses for Q1 2025 were $784,178, a significant decrease from $1.51 million in Q1 2024[168]. Cash Flow and Liquidity - Net cash used in operating activities was approximately $5.0 million for the three months ended March 31, 2025, compared to $8.9 million in the same period of 2024[191]. - As of March 31, 2025, the company had approximately $8.5 million in cash and cash equivalents, down from $20.2 million as of March 31, 2024[191]. - Net cash used in investing activities was approximately $0.5 million, primarily for the purchase of property, plant, and equipment[202]. - Net cash provided by financing activities was approximately $1.2 million, mainly from loans proceeds of approximately $1.0 million from related parties and $0.6 million from third parties, offset by $0.4 million repayment[203]. Contracts and Liabilities - Contractual liabilities for continuing operations rose to $5,102,793 as of March 31, 2025, compared to $4,121,305 as of December 31, 2024, indicating an increase of 23.8%[240]. - Accounts receivable for continuing operations decreased to $3,096,130 as of March 31, 2025, down from $3,281,865 as of December 31, 2024, a decline of 5.6%[240]. - The company recognized $374,384 in revenue from contractual liabilities for the three months ended March 31, 2025, compared to $890,646 in 2024, reflecting a decrease of 57.9%[239]. Future Outlook and Plans - The company plans to continue the rollout of new ECV models and green energy products in North America and Europe over the next twelve months[192]. - The company has invested over approximately $95.2 million in research and development activities since its inception in 2013, with plans to increase R&D expenditure in the long term[195]. - The company expects a decrease in provision for credit losses as sales shift more to FOB terms[161]. - General and administrative expenses are anticipated to decrease over the next two years due to efficiency improvements[160]. Leasing and Facilities - The total annual base rent for two operating lease agreements in Hangzhou, China is $186,866 for the term ending May 2023 and $167,521 for the term ending May 2024[204]. - The lease for a facility in Dusseldorf, Germany has a total annual base rent of approximately $373,630 for the lease term[205]. - A new operating lease agreement in Colombia commenced on May 1, 2023, with a monthly rent of approximately $11,224.92[206]. - The first annual base rent for a facility in Howell, New Jersey is $493,920, with a 3% annual increase[210]. - The monthly rent for a facility in Ontario, California is $115,200 for the first year, increasing to $134,767.71 in the fifth year[209]. Accounting and Financial Reporting - The company is currently assessing the impact of the recently issued ASU No. 2024-03 on its consolidated financial statements, which will improve disclosures about types of expenses[241]. - Shipping and handling costs are recorded as sales and marketing expenses rather than separate performance obligations[235]. - The company has not experienced material costs for quality assurance historically, leading to no accrual for these costs being deemed necessary[235]. - The company has not entered into any off-balance sheet financial guarantees or derivative contracts that are not reflected in the financial statements[214].

WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION MiNK Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 82-2142067 (State or other jurisdiction of incorporation or organization) 149 Fifth Avenue (I.R.S. Employer Identification No.) Suite 500 New York, NY 10010 (Address of principal executive offices) (Zip Code) ...

Financial Performance - Net product revenue for Q1 2025 increased by $0.7 million, or 8.7%, compared to Q1 2024, driven by a $0.5 million increase in Ameluz® sales and $0.2 million from the launch of RhodoLEDXL Lamp[144]. - Total revenues for Q1 2025 were $8.588 million, compared to $7.912 million in Q1 2024, reflecting a change of $0.676 million[144]. - Research and development expenses for Q1 2025 increased by $1.2 million compared to Q1 2024, attributed to the assumption of all clinical trial activities for Ameluz in the U.S.[147]. - Selling, general and administrative expenses decreased by $0.6 million, or 6.5%, in Q1 2025 compared to Q1 2024, with a notable decrease in marketing expenses[146]. - Loss from operations improved by $0.920 million, from a loss of $5.467 million in Q1 2024 to a loss of $4.547 million in Q1 2025[144]. - Net loss for Q1 2025 was $4.203 million, significantly improved from a net loss of $10.437 million in Q1 2024[144]. - Adjusted EBITDA for Q1 2025 was $(4.378) million, an improvement from $(4.577) million in Q1 2024, driven by an increase in gross profit[161]. - The company reported a loss from operations of $4.2 million for the three months ended March 31, 2025, compared to a loss of $10.4 million for the same period in 2024[166][167]. Cash Flow and Capital Management - Cash and cash equivalents as of March 31, 2025, were $1.8 million, down from $5.9 million as of December 31, 2024[162]. - For the three months ended March 31, 2025, net cash used in operating activities was $4.1 million, compared to $3.3 million for the same period in 2024[165][167]. - The net increase in cash and restricted cash for the three months ended March 31, 2025, was a decrease of $4.1 million, compared to an increase of $2.5 million in 2024[165]. - The company had no financing activities during the three months ended March 31, 2025, while it generated $7.7 million from financing activities in the same period of 2024[169]. - The company plans to secure additional capital through equity or debt financings or asset sales to support its commercial and development activities[163]. Compliance and Regulatory Matters - Biofrontera Inc. reported stockholders' equity of $0.5 million as of March 31, 2025, below the Nasdaq requirement of $2.5 million[117]. - The company is in the process of creating a plan to regain compliance with Nasdaq listing standards[117]. - The financial statements have been prepared on a going concern basis, indicating potential adjustments may be necessary if the company cannot continue as a going concern[164]. Product and Market Strategy - The company has reduced the Transfer Price for Ameluz from 50% to 25% of the anticipated net selling price per unit for 2024 and 2025, with planned increases to 35% starting in 2026[114]. - Biofrontera plans to divest its Xepi product line, which has not generated sales since 2023 due to manufacturing delays[116]. - The company is focused on expanding sales of Ameluz and RhodoLED Lamps in the U.S. to establish Ameluz as the standard of care for actinic keratosis[127]. - The company aims to finance R&D activities through the reduced Transfer Price, supporting growth in photodynamic therapy[115]. - The company plans to expand the commercialization of Ameluz in the United States while controlling expenses and limiting capital expenditures[163]. Revenue Generation and Seasonality - Biofrontera's revenues are primarily generated from sales of licensed products, including Ameluz and RhodoLED Lamps[129]. - Biofrontera's revenue is subject to seasonality, with historically higher revenues in the first and fourth quarters[128]. Clinical Trials and Operations - The company has assumed control of all clinical trials related to Ameluz in the U.S. since June 1, 2024, for better cost management[115]. - The change in fair value of warrant liabilities was a gain of $0.548 million in Q1 2025, compared to a loss of $3.429 million in Q1 2024[149]. - The company experienced a change in fair value of warrant liabilities of $0.5 million for the three months ended March 31, 2025[166]. - The company had negligible fixed asset purchases during the three months ended March 31, 2025[168]. - There were no material changes to the company's critical accounting estimates for the three months ended March 31, 2025[172].